Clinical Significance of erbB-2 (HER-2/neu) Protein

References

• King C R, Kraus M H, Aaronson S A. Amplification of a novel v-erbB related gene in a human mammary carcinoma. Science 1985; 229: 974–976
   PubMed Web of Science ®Google Scholar
• Coussens L, Yang-Feng T L, Liao Y C. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230: 1130–1139
   Google Scholar
• Bargman C J, Hung M C, Weinberg R A. The neu oncogene encodes an epidermal growth factor receptor related protein. Nature 1986; 319: 230–234
   PubMedGoogle Scholar
• Lupu R, Colomer R, Zugmaier G. Direct interaction of a ligand for erbB-2 oncogene product with the EGF receptor and pl85erbB-2. Science 1990; 249: 1552–1555
   PubMed Web of Science ®Google Scholar
• Fazioli F, Kim U H, Rhee S G. The erbB-2 mitogenic signaling pathway; tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency. Mol Cell Biol 1991; 11(4)2040–2048
   PubMed Web of Science ®Google Scholar
• Lonardo F, Di Marco E, King C R. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol 1990; 2(11)992–1003
   PubMedGoogle Scholar
• Paik S M, Hazan R, Fisher E R. Pathologic findings from the NSABP: prognostic significance of erbB-2 protein over-expression in primary breast cancer. J Clin Oncol 1990; 8: 103–112
   PubMed Web of Science ®Google Scholar
• Kern J A, Schwartz D A, Nordberg J E. pl85neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 1990; 50: 5184–5187
   PubMed Web of Science ®Google Scholar
• Slamon D J, Godolphin W, Jones L A. Studies of the HER-21 neu proto-oncogene in human breast and ovarian cancer. Science 1989; 224: 707–712
   Google Scholar
• Yonemura Y, Ninomiya I, Yamaguchi A. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res 1991; 51: 1034–1038
   PubMed Web of Science ®Google Scholar
• Hall P A, Hughes C M, Staddon S L. The c-erbB-2 pro-tooncogene in human pancreatic cancer. J Pathol 1990; 161: 195–200
   PubMed Web of Science ®Google Scholar
• Berchuck A, Rodriguez G, Kinney R B. Overexpression of HER-21 neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991; 164: 15–21
   PubMed Web of Science ®Google Scholar
• Kraus M H, Popescu N C, Amsbaugh C. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary carcinoma cell lines by different molecular mechanisms. EMBO J 1987; 6: 605–610
   PubMed Web of Science ®Google Scholar
• Perren T J. c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 1991; 63: 328–332, (editorial)
   PubMed Web of Science ®Google Scholar
• Paik S M, Simpson S, King C R, Lippman M E. Quantification of erbB-2lneu levels in tissue. Methods Enzymol 1991; 198: 290–302
   PubMed Web of Science ®Google Scholar
• Van de Vijver M J, Peterse J L, Mooi W J. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage 11 breast cancer. N Engl J Med 1988; 319(19)1239–1245
   PubMed Web of Science ®Google Scholar
• Ramachandra S, Machin L, Ashley S. Immunohistochem-ical distribution of c-erbB-2 in in situ breast carcinoma–a detailed morphological analysis. J Pathol 1990; 161(1)7–14
   PubMed Web of Science ®Google Scholar
• Battifora H, Gaffey M, Esteban J. Immunohistochemical assay of neulc-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Modern Pathol 1991; 4: 466–474
   PubMed Web of Science ®Google Scholar
• Winstanley J, Cooke T, Murray C D. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991; 63: 447–450
   PubMed Web of Science ®Google Scholar
• Anbazhagan R, Gelber R D, Bettelheim R. Association of c-erbB-2 expression and S-phase fraction in the prognosis of node positive breast cancer. Ann Oncol 1991; 2: 47–53
   PubMed Web of Science ®Google Scholar
• Borg A, Baldetorp B, Ferno M. erbB-2 amplification in breast cancer with a higher rate of proliferation. Oncogene 1991; 6: 137–143
   PubMed Web of Science ®Google Scholar
• Wright C, Nicholson S, Angus B. Association of c-erbB-2 oncoprotein expression with lack of response to endocrine therapy in recurrent breast cancer. J Pathol, 158: 350A, (abstr)
   Google Scholar
• Benz C C, Scott G K, Sarup J C. Tamoxifen resistance aserbB-2 (HER-2/neu) Protein sociated with pl85HER-2 overexpression in human breast cancer cells transfected with HER-2/neu. Proc AACR 1991; 32: 1260A, (abstr)
   Google Scholar
• Hudziak R M, Lewis G D, Winget M. Pl85HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9(3)1165–1172
   PubMed Web of Science ®Google Scholar
• Brysch W, Magal E, Louis J C. Inhibiting c-er6B-2 over-expression in human mammary carcinoma cells with phospho-thioate oligodeoxynucleotides. Proc Annu Meet Am Assoc Cancer Res; 1991; 32: 2574A, (abstr)
   Google Scholar
• Mori S, Akiyama T, Morishita Y. Light and electron microscopical demonstration of c-erbB-2 gene product-like im-munoreactivity in human malignant tumors. Virchows Arch B 1987; 54: 8–15
   Google Scholar
• Yokota J, Yamamoto T, Toyoshima K. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1986; 1: 765–767
   PubMed Web of Science ®Google Scholar
• Park J B, Rhim J S, Park S C. Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas. Cancer Res 1989; 49: 6605–6609
   PubMed Web of Science ®Google Scholar
• Yokota J, Yamamoto T, Miyajima N. Genetic alterations of c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988; 2: 283–287
   PubMed Web of Science ®Google Scholar
• Falck V G, Gullick W J. c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study. J Pathol 1989; 159: 107–111
   PubMed Web of Science ®Google Scholar
• Kameda T, Yasui W, Yoshida K. Expression of erbB-2 in human gastric carcinomas: relationship between pl85rfcB-2 expression and the gene amplification. Cancer Res 1990; 50: 8002–8009
   PubMed Web of Science ®Google Scholar
• Paik S M, Chung H C, Yang W I. Overexpression of erbB-2 protein in gastric cancer. Proc Annu Meet Am Assoc Cancer Res; 1991; 32: A1730, (abstr)
   Google Scholar
• Hancock M C, Chan A W, Mischak R P. Monoclonal antibodies to c-erbB-2 enhance the cytotoxicity of cisplatin against human breast and ovarian tumor cells. J Cell Biochem 1990; CF203, (Suppl 14B)
   Google Scholar
• Shepard H M, Lewis G D, Sarup J C, Fendly B M. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 1991; 11(3)117–127
   PubMed Web of Science ®Google Scholar